BE
Therapeutic Areas
Cogent Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Bezuclastinib | Non-Advanced Systemic Mastocytosis (NonAdvSM) | NDA Submitted |
| FGFR2 Program | FGFR2-driven cancers | Preclinical |
| ErbB2 Program | ErbB2 (HER2) mutant cancers | Preclinical |
| PI3Kα Program | PI3Kα mutant cancers | Preclinical |
Leadership Team at Cogent Biosciences
AR
Andrew Robbins
Chief Executive Officer and President
JS
Jessica Sachs, MD
Chief Medical Officer
CP
Cole Pinnow
Chief Commercial Officer
JR
John Robinson, PhD
Chief Scientific Officer
BB
Brad Barnett
Chief Technology Officer
ES
Erin Schellhammer
Chief People Officer
EK
Evan Kearns, JD
Chief Legal Officer and Corporate Secretary
JG
John Green
Chief Financial Officer
BF
Brad Fell
Senior Vice President, Chemistry
FS
Francis Sullivan, PhD
Senior Vice President, Enzymology & Structural Biology